Abstract
Purpose
Mean platelet volume (MPV) and neutrophil to lymphocyte ratio (NLR) are the new markers of the detection of inflammation. Our aim is to investigate MPV and NLR in lean and obese patients with polycystic ovary syndrome (PCOS).
Methods
This study was designed to investigate MPV, NLR, and high-sensitive C-reactive protein (hsCRP) levels in 25 obese patients with PCOS and 16 lean patients with PCOS, and our study group was matched with 16 obese and 14 non-obese controls, respectively.
Results
PCOS group had higher MPV, NLR, neutrophil count, neutrophil to total leucocyte ratio, basophil count, waist circumference (WC), insulin, glucose, and HOMA-IR rates than those of controls. hsCRP levels were similar in both groups. Subgroup analyses revealed that obese PCOS group had higher insulin and HOMA-IR levels, compared to those of controls. In this subgroup, total leucocyte counts, MPV, and hsCRP levels were similar. On the other hand, lean PCOS group had higher WC, NLR, MPV, and basophil count than controls. In correlation analysis, hsCRP was positively correlated with body mass index (BMI), WC, total leucocyte count, neutrophil count, while negatively correlated with lymphocyte ratio. Although leucocyte count was positively correlated with BMI, MPV was negatively correlated with BMI, total leucocyte, platelet, and neutrophil counts. NLR was positively correlated with HOMA-IR, hsCRP, BMI, WC, and insulin.
Conclusion
Our study demonstrated that MPV and NLR levels are increased despite similar hsCRP levels in patients with PCOS. However, we failed to demonstrate these differences in obese PCOS patients. Further studies with larger sample size are required to determine the significance of BMI in the inflammation of PCOS patients.
Similar content being viewed by others
References
Nandi A, Chen Z, Patel R, Poretsky L (2014) Polycystic ovary syndrome. Endocrinol Metab Clin North Am 43(1):123–147. doi:10.1016/j.ecl.2013.10.003
Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K (2012) Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97(1):28–38e25. doi:10.1016/j.fertnstert.2011.09.024
Chen L, Xu WM, Zhang D (2014) Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome. Fertil Steril 102(4):1167–1174e1164. doi:10.1016/j.fertnstert.2014.06.027
Keskin Kurt R, Okyay AG, Hakverdi AU, Gungoren A, Dolapcioglu KS, Karateke A, Dogan MO (2014) The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study. Arch Gynecol Obstet 290(2):315–319. doi:10.1007/s00404-014-3199-3
Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86(6):2453–2455. doi:10.1210/jcem.86.6.7580
Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C (2004) Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89(11):5592–5596. doi:10.1210/jc.2004-0751
Ruan X, Dai Y (2009) Study on chronic low-grade inflammation and influential factors of polycystic ovary syndrome. Med Princ Pract 18(2):118–122. doi:10.1159/000189809
Bloomgarden ZT (2003) Inflammation and insulin resistance. Diabetes Care 26(5):1619–1623
Dandona P, Aljada A, Chaudhuri A, Bandyopadhyay A (2003) The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab 88(6):2422–2429. doi:10.1210/jc.2003-030178
Wilson PW, Kannel WB, Silbershatz H, D’Agostino RB (1999) Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159(10):1104–1109
Ravn P (2015) New paradigms in PCOS: Impaired glucose tolerance and cardiovascular risk. Clinical approach. Minerva Ginecologica
Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84(1):165–169. doi:10.1210/jcem.84.1.5393
Kahal H, Aburima A, Ungvari T, Rigby AS, Dawson AJ, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL (2013) Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clin Endocrinol 79(2):252–258. doi:10.1111/cen.12137
Kim JW, Han JE, Kim YS, Won HJ, Yoon TK, Lee WS (2012) High sensitivity C-reactive protein and its relationship with impaired glucose regulation in lean patients with polycystic ovary syndrome. Gynecol Endocrinol 28(4):259–263. doi:10.3109/09513590.2011.613967
Herlihy AC, Kelly RE, Hogan JL, O’Connor N, Farah N, Turner MJ (2011) Polycystic ovary syndrome and the peripheral blood white cell count. J Obstet Gynaecol 31(3):242–244. doi:10.3109/01443615.2011.553693
Phelan N, O’Connor A, Kyaw Tun T, Correia N, Boran G, Roche HM, Gibney J (2013) Leucocytosis in women with polycystic ovary syndrome (PCOS) is incompletely explained by obesity and insulin resistance. Clin Endocrinol 78(1):107–113. doi:10.1111/j.1365-2265.2012.04454.x
Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, Grimm RH Jr, Howard BV, Assaf AR, Prentice R, Women’s Health Initiative Research G (2005) Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women’s Health Initiative Observational Study. Arch Intern Med 165(5):500–508. doi:10.1001/archinte.165.5.500
Celikbilek M, Dogan S, Ozbakir O, Zararsiz G, Kucuk H, Gursoy S, Yurci A, Guven K, Yucesoy M (2013) Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal 27(1):72–76. doi:10.1002/jcla.21564
Imtiaz F, Rashed MS, Al-Mubarak B, Allam R, El-Karaksy H, Al-Hassnan Z, Al-Owain M, Al-Zaidan H, Rahbeeni Z, Qari A, Meyer BF, Al-Sayed M (2011) Identification of mutations causing hereditary tyrosinemia type I in patients of Middle Eastern origin. Mol Genet Metab 104(4):688–690. doi:10.1016/j.ymgme.2011.06.019
Demir M, Cosar S, Melek M (2014) Evaluation of plasma eosinophil count and mean platelet volume in patients with coronary slow flow. Clinics 69(5):323–326
Sahin DY, Gur M, Elbasan Z, Yildirim A, Akilli RE, Koyunsever NY, Ozaltun B, Gozubuyuk G, Kivrak A, Cayli M (2014) Mean platelet volume associated with aortic distensibility, chronic inflammation, and diabetes in patients with stable coronary artery disease. Clin Appl Thromb Hemost 20(4):416–421. doi:10.1177/1076029612468941
Coban E, Yazicioglu G, Berkant Avci A, Akcit F (2005) The mean platelet volume in patients with essential and white coat hypertension. Platelets 16(7):435–438. doi:10.1080/09537100500163572
Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD (2011) Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 17(1):47–58
Schafer A, Bauersachs J (2008) Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 6(1):52–60
Tavil Y, Sen N, Yazici H, Turfan M, Hizal F, Cengel A, Abaci A (2010) Coronary heart disease is associated with mean platelet volume in type 2 diabetic patients. Platelets 21(5):368–372. doi:10.3109/09537101003628421
Gursoy A, Ertugrul DT, Pamuk B, Sahin M, Asik M, Yilmaz H, Haydardedeoglu F, Tutuncu NB, Demirag NG (2006) Mean platelet volume in patients with polycystic ovary disease. Platelets 17(7):505–506. doi:10.1080/09537100600901590
Kabil Kucur S, Gozukara I, Aksoy A, Uludag EU, Keskin H, Kamalak Z, Carlioglu A (2014) How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome? Blood Coagul Fibrinolysis. doi:10.1097/MBC.0000000000000229
Kebapcilar L, Taner CE, Kebapcilar AG, Sari I (2009) High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 280(2):187–193. doi:10.1007/s00404-008-0884-0
Rotterdam EA-SPCWG (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19–25
Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D (2006) Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 36(10):691–697. doi:10.1111/j.1365-2362.2006.01712.x
Farhangi MA, Keshavarz SA, Eshraghian M, Ostadrahimi A, Saboor-Yaraghi AA (2013) White blood cell count in women: relation to inflammatory biomarkers, haematological profiles, visceral adiposity, and other cardiovascular risk factors. J Health Popul Nutr 31(1):58–64
Silfeler DB, Kurt RK, Yengil E, Un B, Arica S, Baloglu A (2014) Evaluation of Mean Platelet Volume values in lean women with polycystic ovary syndrome. Pak J Med Sci 30(3):589–592. doi:10.12669/pjms.303.4475
Dogan BA, Arduc A, Tuna MM, Karakilic E, Dagdelen I, Tutuncu Y, Berker D, Guler S (2014) Association of mean platelet volume with androgens and insulin resistance in nonobese patients with polycystic ovary syndrome. Int J Endocrinol Metab 12(4):e18642. doi:10.5812/ijem.18642
Coban E, Ozdogan M, Yazicioglu G, Akcit F (2005) The mean platelet volume in patients with obesity. Int J Clin Pract 59(8):981–982. doi:10.1111/j.1742-1241.2005.00500.x
Papalou O, Livadas S, Karachalios A, Tolia N, Kokkoris P, Tripolitakis K, Diamanti-Kandarakis E (2015) White blood cells levels and PCOS: direct and indirect relationship with obesity and insulin resistance, but not with hyperandrogenemia. Hormones 14(1):91–99. doi:10.14310/horm.2002.1563
Acknowledgments
Authors thank Numan Duran for language editing. This study was supported by Konya Training and Research Hospital’s Research Fund.
Conflict of interest
The authors declared no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yilmaz, M.A., Duran, C. & Basaran, M. The mean platelet volume and neutrophil to lymphocyte ratio in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 39, 45–53 (2016). https://doi.org/10.1007/s40618-015-0335-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-015-0335-2